Compare KBSX & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KBSX | NSRX |
|---|---|---|
| Founded | 1976 | 2019 |
| Country | Taiwan | Israel |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.4M | 63.4M |
| IPO Year | N/A | 2025 |
| Metric | KBSX | NSRX |
|---|---|---|
| Price | $1.34 | $6.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.50 |
| AVG Volume (30 Days) | 7.4K | ★ 9.0K |
| Earning Date | 02-11-2026 | 02-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $44,890,395.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 30.46 | N/A |
| 52 Week Low | $1.26 | $5.90 |
| 52 Week High | $8.99 | $9.99 |
| Indicator | KBSX | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.71 | N/A |
| Support Level | $1.33 | N/A |
| Resistance Level | $1.60 | N/A |
| Average True Range (ATR) | 0.02 | 0.00 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
FST Corp is a renowned manufacturer and innovator in the golf industry with a growing portfolio of creative golf products, including acclaimed golf club shafts and other equipment. The Company has engaged in the research, development, manufacturing, and sales of golf club shafts. The Company currently produces and sells golf club shafts under the Company's own high performance KBS golf club shaft brand, and serves as an original equipment manufacturer (OEM) and original design manufacturer (ODM) for other world-renowned golf equipment brands, golf equipment OEMs, and golf equipment distributors that provide consumers with customized golf club services.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.